Status: Recruiting
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg/day, 1200 mg/day, 1800 mg/day for 28 days (cycle), until progression or toxicity.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Pierluigi PorcuUpdated: Jun 25, 2026Locations: 1
Eligibility criteria
Age ≥ 18 years. [+15]
Patients with severe or active symptomatic cardiopulmonary diseases (unstable an... [+12]